Purpose of review 

Obesity is increasing in prevalence among patients with type 1 diabetes (T1D) and is associated with insulin resistance and increased cardiovascular risk. The management of obesity in this population is complicated by defects in pancreatic islet hormone secretion and the effects of exogenous insulin treatment. Here, we review the effects of antiobesity medications and adjunct-to-insulin medications on body weight in T1D.

Recent findings 

There is a profound evidence gap around the use of drugs for the treatment of obesity in T1D since systematic studies have not been performed in this population. Adjunctive-to-insulin therapy with certain antihyperglycemic agents leads to modest weight loss and reductions in insulin dose in T1D. However, only pramlintide has been approved in the United States for clinical use as adjunctive therapy in T1D.

Summary 

The growing prevalence of obesity in T1D has created an unmet need for safe and effective therapies to treat overweight and obesity in this population. Currently, antiobesity medications are used off-label for the treatment of patients with T1D. Additional studies are needed to understand the role of these medications in the management of obesity in patients with T1D.

中文翻译：

---

解决1型糖尿病肥胖的药理疗法。

审查目的 

肥胖症在1型糖尿病（T1D）患者中的患病率正在增加，并且与胰岛素抵抗和心血管风险增加相关。在该人群中，肥胖的管理因胰岛激素分泌缺陷和外源性胰岛素治疗的影响而变得复杂。在这里，我们回顾了抗肥胖药和胰岛素辅助药物对T1D体重的影响。

最近的发现 

由于尚未对该人群进行系统的研究，因此在T1D中使用药物治疗肥胖症方面存在着深刻的证据空白。某些抗高血糖药对胰岛素的辅助治疗可导致适度的体重减轻和T1D患者胰岛素剂量的减少。但是，在美国，只有普兰林肽被批准用于T1D的辅助治疗。

概要 

肥胖症在T1D中的患病率日益上升，因此，对于治疗该人群中超重和肥胖症的安全有效方法的需求未得到满足。目前，减肥药已被标签外用于治疗T1D患者。需要更多的研究来了解这些药物在T1D患者肥胖管理中的作用。